Medication info

Samsung Pioglitazone Tablets 15 mg (Pioglitazone Hydrochloride)

Prescription medicationApproval withdrawn
Ingredient · strength
Pioglitazone Hydrochloride›Strength being verified
Manufacturer / importer
Samsung Pharm. Co., Ltd.
Appearance
White round tablets
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 201805174 · Approved 2018.12.19

This product's status changed to Approval withdrawn on 2023.08.11. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults · Children
Adult dosage
Administer orally once daily, regardless of meals. 1. Monotherapy In patients whose blood glucose is not adequately controlled with diet and exercise, treatment may be initiated with pioglitazone 15 mg once daily. If the initial dose does not provide an adequate effect, the dose may be increased to 30 mg once daily. 2. Combination therapy 1) Sulfonylureas: The initial dose is 15 mg once daily. When used in combination therapy, the current sulfonylurea may be continued at the same dosage regimen. If symptoms of hypoglycemia occur, the dose of the sulfonylurea should be reduced. 2) Metformin: The initial dose is 15 mg once daily. When used in combination therapy, the current metformin may be continued at the same dosage regimen. 3) Insulin: Administer 15 mg once daily. The current insulin dose may be maintained when initiating combination therapy. If symptoms of hypoglycemia occur or plasma glucose decreases to 100 mg/dL or less, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. Maximum recommended dose: For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Treatment should be continued for an adequate period to assess changes in glycated hemoglobin (at least 3 months).
Children's dosage
Under 18 years: Use is not recommended because there is no experience with this medicine.

Ingredients

Manufacturer
Samsung Pharm. Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Blood sugar control issues in patients with type 2 diabetes
View approved original text

This medication is used as an adjunct to dietary and exercise therapy for blood sugar control in patients with type 2 diabetes. It can be administered as a monotherapy, but if there is no blood sugar improvement with other oral hypoglycemic agents, it is used in combination with sulfonylureas, metformin, or insulin. Furthermore, patients with type 2 diabetes are required to follow nutritional counseling and weight loss, as well as maintaining a regular exercise regimen, as these efforts are crucial not only for initial treatment but also for sustaining the effectiveness of drug therapy. This medication effectively improves blood sugar control in patients with type 2 diabetes.

Dosage and Administration

Adult dosage

Administer orally once daily, regardless of meals. 1. Monotherapy In patients whose blood glucose is not adequately controlled with diet and exercise, treatment may be initiated with pioglitazone 15 mg once daily. If the initial dose does not provide an adequate effect, the dose may be increased to 30 mg once daily. 2. Combination therapy 1) Sulfonylureas: The initial dose is 15 mg once daily. When used in combination therapy, the current sulfonylurea may be continued at the same dosage regimen. If symptoms of hypoglycemia occur, the dose of the sulfonylurea should be reduced. 2) Metformin: The initial dose is 15 mg once daily. When used in combination therapy, the current metformin may be continued at the same dosage regimen. 3) Insulin: Administer 15 mg once daily. The current insulin dose may be maintained when initiating combination therapy. If symptoms of hypoglycemia occur or plasma glucose decreases to 100 mg/dL or less, the insulin dose may be reduced by 10 ~ 25 %. Subsequent dose adjustments should be individualized according to glycemic control. Maximum recommended dose: For monotherapy or combination therapy with a sulfonylurea, metformin, or insulin, doses exceeding 30 mg once daily are not recommended. Treatment should be continued for an adequate period to assess changes in glycated hemoglobin (at least 3 months).

Children's dosage

Under 18 years: Use is not recommended because there is no experience with this medicine.

Precautions

This medication is primarily used for blood sugar control in patients with type 2 diabetes. This medication may place a burden on the heart, and should not be used in patients with heart failure or a history of heart failure. Particularly, if symptoms or signs of heart failure appear, immediate medical attention should be sought, and if necessary, the administration of this medication should be stopped or the dosage reduced. Moreover, this medication can cause fluid retention, potentially worsening edema or heart failure, so patients with edema or heart disease should be closely monitored. Patients with active bladder cancer or a history of bladder cancer, liver impairments, severe kidney disorders, and diabetic ketoacidosis should not receive this medication. Women who are pregnant or may become pregnant, as well as certain genetically lactose intolerant patients should also refrain from taking this medication. When used in combination with other hypoglycemic agents, the risk of hypoglycemia may increase, so one should be well-informed about hypoglycemia symptoms and appropriate responses. During treatment, regular monitoring of liver function tests and blood sugar control status is necessary, and if unusual symptoms such as weight gain, edema, or shortness of breath appear, immediate consultation with a physician is advised. Some premenopausal women may experience ovulation as a result of this medication, so it is recommended to use appropriate contraceptive methods during treatment. This medication is taken once daily regardless of meals, and in case of a missed dose, care should be taken not to double the dose the next day. Finally, the safety and efficacy in children have not been established, and caution should be exercised in elderly patients. It is important to promptly consult a physician or pharmacist if any unusual symptoms or suspicious signs occur during the course of treatment.

Side effects

Congestive heart failure, excessive and rapid weight changes, shortness of breath, edema, fluid retention, edema, upper respiratory infection, headache, sinusitis, myalgia, pharyngitis, abdominal distension, weight gain, hypoglycemia, urinary tract infection, low back pain, dizziness, diarrhea, elevated serum creatine kinase, hypertension, heart failure, limb pain, chest pain, death due to cardiovascular predisposition, worsening of congestive heart failure, emergency room visit due to congestive heart failure, progression of congestive heart failure, edema, liver failure, diabetic macular edema accompanied by decreased vision, hepatotoxicity, reduction in hemoglobin, elevated serum ALT levels, increased serum creatinine, dizziness, loss of appetite, constipation, upper abdominal pain, chest pain, fatigue, weakness, dyspepsia, nausea, shortness of breath, itching, chest discomfort, tremors, chills, gastrointestinal disease, abdominal pain, discomfort in the epigastric region, numbness, muscle rigidity, discomfort in the head, worsening of liver disease, urticaria, eczema, arthralgia, knee abnormality, arm weakness, proteinuria, anxiety, insomnia, drowsiness, simple herpes, blurred vision, orthostatic hypotension, palpitations, stroke, sexual dysfunction, myocardial infarction, fracture, increased blood sugar, elevated serum creatine kinase

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a container that can block light and air, and moisture-laden areas should be avoided. The storage temperature should be maintained between 15 degrees and 30 degrees, ideally around 25 degrees.

Appearance and packaging

Appearance

White round tablets

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.